# Regulatory Compliance in the Rheumatology Domain

## Overview

Regulatory compliance requirements shape the design of the rheumatology domain model by imposing constraints on data handling, drug safety monitoring, and quality reporting. In the United States, HIPAA governs patient data privacy and security, the FDA regulates biologic therapy approval and pharmacovigilance, and CMS mandates quality measure reporting. In Europe, the EMA governs biologic regulation and GDPR controls personal data processing. These regulations are not bolted on as afterthoughts but are built into the domain model as invariants, value objects, and domain rules.

## HIPAA Compliance

### Privacy Rule

The HIPAA Privacy Rule restricts how protected health information (PHI) is used and disclosed. In the rheumatology domain model, this affects how patient data flows between bounded contexts. Each context must implement minimum necessary standards, meaning it receives only the PHI needed for its specific function. The AssessmentCompleted event carries clinical findings but not full patient demographics. The TherapyStarted event carries the drug and dosing information but not the patient's full medical history.

The domain model enforces purpose limitation through context boundaries. The Biologic Therapy Context receives therapy-relevant clinical data (diagnosis, prior treatments, contraindications) but not unrelated clinical information. The Pain Management Context receives pain-relevant assessment data but not full serology panels.

### Security Rule

The HIPAA Security Rule requires administrative, physical, and technical safeguards for electronic PHI. In the domain model, this manifests as access control rules embedded in repository interfaces (who can access what data), audit logging requirements (all data access must be recorded), and encryption requirements (PHI at rest and in transit must be encrypted).

Repository implementations must log every access to patient data, including the user, timestamp, data accessed, and purpose. The event store records all inter-context communication, providing a complete audit trail of how clinical data flowed through the system.

### Breach Notification

The domain model must support breach detection and notification. If unauthorized access to PHI is detected, the system must identify which patients' data was accessed, what data elements were exposed, and when the access occurred. The audit logging infrastructure in each repository supports this requirement.

## FDA Requirements

### Biologic Drug Regulation

Biologic DMARDs are regulated by the FDA under the Public Health Service Act. The Biologic Therapy Context must enforce FDA-mandated requirements including approved indications (adalimumab is FDA-approved for RA, psoriatic arthritis, ankylosing spondylitis, and other conditions; the domain model validates that the prescribed indication matches an approved use), black box warnings (JAK inhibitors carry boxed warnings for serious infections, malignancy, cardiovascular events, and thrombosis that must be documented in the prescribing workflow), and Risk Evaluation and Mitigation Strategies (REMS) for specific drugs.

### Biosimilar Regulation

The FDA regulates biosimilar approval under the Biologics Price Competition and Innovation Act. The domain model's BiosimilarSwitch entity captures FDA requirements including the distinction between biosimilar and interchangeable products (interchangeable products may be substituted at the pharmacy without prescriber intervention, while non-interchangeable biosimilars require prescriber-directed switching), naming conventions with distinguishing suffixes (adalimumab-atto, adalimumab-bwwd), and post-marketing surveillance requirements.

### Adverse Event Reporting

The FDA MedWatch program requires reporting of serious adverse events associated with biologic therapies. The Biologic Therapy Context models adverse event severity classification (mild, moderate, severe, life-threatening, fatal), causality assessment (definite, probable, possible, unlikely, unrelated), and reporting obligations (serious events must be reported within 15 days; periodic safety update reports are required). The InfusionReactionOccurred event captures data in a format that supports MedWatch reporting.

### Post-Marketing Surveillance

The FDA requires ongoing safety monitoring after drug approval. The domain model supports post-marketing surveillance through the TherapyRegimen aggregate's SafetyMonitoring entity, which tracks long-term safety outcomes including infection rates, malignancy occurrence, cardiovascular events, and immunogenicity (development of anti-drug antibodies).

## EMA Requirements

### European Biologic Regulation

The European Medicines Agency regulates biologic therapies under the centralized authorization procedure. The domain model accommodates EMA-specific requirements where applicable, including Summary of Product Characteristics (SmPC) compliance, Periodic Safety Update Reports (PSURs), and the European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP) guidelines.

### Pharmacovigilance

EMA pharmacovigilance requirements are modeled in the Biologic Therapy Context. The Pharmacovigilance value object tracks Individual Case Safety Reports (ICSRs) using the ICH E2B format, signal detection from accumulated adverse event data, and risk management plans (RMPs) that define additional monitoring activities for specific drugs.

## Quality Reporting Requirements

### CMS MIPS

The Centers for Medicare and Medicaid Services Merit-based Incentive Payment System requires reporting of quality measures. The Outcomes Tracking Context generates reports for rheumatology-relevant measures including disease activity assessment and classification documentation (measures how frequently disease activity scores are calculated and documented), functional status assessment (measures HAQ-DI or equivalent functional assessment frequency), and appropriate screening before biologic initiation (measures tuberculosis screening rates).

### HEDIS Measures

Healthcare Effectiveness Data and Information Set measures relevant to rheumatology include Disease-Modifying Anti-Rheumatic Drug Therapy for Rheumatoid Arthritis, which measures the percentage of RA patients prescribed a DMARD. The Outcomes Tracking Context supports this measure by tracking DMARD prescription status for all RA patients.

## Compliance as Domain Rules

Regulatory requirements are modeled as domain rules rather than external constraints. Pre-treatment screening before biologic therapy is a domain invariant, not just a regulatory checkbox. Adverse event documentation is a domain event with clinical significance, not just a reporting obligation. Minimum necessary data sharing is enforced by context boundaries, not just by access control lists.

This approach ensures that regulatory compliance is maintained even as the system evolves. New regulations are incorporated by adding or modifying domain rules, value objects, and invariants rather than by bolting on compliance checks at the infrastructure layer.

## References

- Evans, Eric. Domain-Driven Design: Tackling Complexity in the Heart of Software. Addison-Wesley, 2003.
- Vernon, Vaughn. Implementing Domain-Driven Design. Addison-Wesley, 2013.
- Khononov, Vlad. Learning Domain-Driven Design. O'Reilly Media, 2021.
- U.S. Department of Health and Human Services. "HIPAA Privacy Rule." 45 CFR Part 160 and Part 164.
- U.S. Food and Drug Administration. "Biosimilar and Interchangeable Biologics: More Treatment Choices." FDA, 2023.
- European Medicines Agency. "Guideline on Good Pharmacovigilance Practices." EMA, 2022.
- Centers for Medicare and Medicaid Services. "Quality Payment Program: MIPS." CMS, 2023.
